Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

29.15 +0.76 (+2.68%)
Streaming Delayed Price Updated: 9:34 AM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cassava Sciences Inc

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
20 21 Next >
Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market
Cortexyme is testing a twice-day pill to treat Alzheimer's disease. 
Via Investor's Business Daily
3 Biotech Stocks That Are Ridiculously Overpriced
They've risen too far, too quickly. 
Via The Motley Fool
It Turns Out That The World Still Needs Coal: Good News For Our Recent Top Name, Peabody Energy
A Liebherr mining truck at dusk at Peabody's North Antelope Rochelle Mine in the Powder River Basin of Wyoming (photo via Peabody). It Turns Out The World... 
Via Benzinga
It Turns Out The World Still Needs Coal
Peabody Energy (BTU), whose shares spiked 23% on Monday after the company announced that its coal revenue in Q3 would be the highest in seven quarters and it offered bullish forward guidance. 
Via Talk Markets
Exposures Coal
Crisis Investing
From COVID, to energy, to supply chain breakdowns, the market has been buffeted by crises recently. How we've navigated them so far. 
Via Talk Markets
Crisis Investing: From COVID, To Energy, To Supply Chain Breakdowns, The Market Has Been Buffeted By Crises Recently. How We've Navigated Them So Fa.
A Gadsden flag hung out of a Southwest Airlines 737 cockpit. Photo via American Greatness. A Market Buffeted By Bad News The apparent work slowdown at... 
Via Benzinga
Exposures Labor
Cassava Sciences: Fine Trading Stock, Terrible Investment
SAVA stock may be fun to trade, but the long-term prognosis is grim 
Via InvestorPlace
Topics Fraud
Exposures Legal
Cassava Sciences Starts Late-Stage Simufilam Study In Alzheimer's Patients
Cassava Sciences Inc (NASDAQ: SAVA) initiated an initial Phase 3 efficacy study of simufilam, an investigational drug for patients with Alzheimer's disease.... 
Via Benzinga
Cassava Sciences Stock Could Explode as FDA Approval Is a Real Possibility
SAVA stock is volatile but worthwhile as its Alzheimer's drug inches closer to commercialization. Risk tolerance is needed, though. 
Via InvestorPlace
Exposures Product Safety
Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases
Image by Gerd Altmann from Pixabay How well we think, feel and act rests in the hands of trillions of tiny connectors in our minds. Synapses play an integral role in how we... 
Via Benzinga
How David Green Traded Moderna For A Big Profit On Monday Morning
David Green was back live trading on Benzinga TV on Monday morning. Here's a recap of what he traded and discussed. Big Winners Of The Day Green's best trade on... 
Via Benzinga
Use Cassava Sciences Stock Weakness as Buy Opportunity Ahead of Phase 3
If Cassava Sciences' Alzheimer drug can continue to produce solid results, it could see FDA approval before the end of 2022. SAVA stock may not be oversold for long. 
Via InvestorPlace
Exposures Product Safety
What to Make of Cassava Sciences’ Late September Rally
Cassava Sciences gained 50% in the second half of September. Now the question is, can SAVA stock keep up momentum in October? 
Via InvestorPlace
Cassava Stock Has Reached a Positive Turning Point
Cassava is rebounding and SAVA stock may rally back to its old highs as it fends off a short-selling attack. 
Via InvestorPlace
The Good News Is Piling Up for Cassava Stock
Recent news indicates that the FDA is going to reject a petition against Cassava, helping to make SAVA stock very attractive. 
Via InvestorPlace
Exposures Product Safety
Is Cassava Sciences Back in the Game?
There's nothing spectacular about the latest results for the company's flagship drug. 
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Molecular Templates (NASDAQ:MTEM) stock rose 14.13% to $7.59 during Friday's regular session. Trading volume for Molecular Templates's stock is 937.9K as... 
Via Benzinga
Why Shares of Cassava Sciences Rose 15% Today
Additional data is promising. But will investors trust it? 
Via The Motley Fool
B. Riley Says Alzheimer's Data From This Firm Has Renewed 'Investor Confidence'
B. Riley says yesterday's readout from a pre-planned 12-month treatment interim analysis of Cassava Sciences Inc's (NASDAQ: SAVA) simufilam trial data... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers TransCode Therapeutics (NASDAQ:RNAZ) stock rose 94.3% to $5.09 during Thursday's regular session. TransCode Therapeutics's stock is trading at a volume of... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares surged 73.4% to close at $12.80 on Thursday following news the company will buy ZACC Kabushiki Kaisha for $3.362... 
Via Benzinga
SAVA Stock: What Is Going on With Red-Hot Cassava Sciences Today?
Today, Cassava Sciences initially soared on the announcement of some positive preliminary data, before SAVA stock began selling off. 
Via InvestorPlace
The Cassava Sciences Saga Rages On — Why This Alzheimer's Update Didn't Save It
Cassava said patients who received its Alzheimer's drug showed improved cognition. 
Via Investor's Business Daily
Cassava Sciences' Simufilam Data Shows Improved Cognition In Alzheimer's Disease
Cassava Sciences Inc (NASDAQ: SAVA) has announced top-line data from a pre-planned interim analysis of an ongoing open-label study of simufilam in mild-to-moderate... 
Via Benzinga
Cassava Sciences Can Recover Despite Harsh Allegations
SAVA stock dove after a law firm made statements against the company. However, Cassava's CEO isn't just taking it lying down. 
Via InvestorPlace
The Cassava Saga: Here's What You Need To Know About This Embattled Alzheimer's Stock
Cassava Sciences could hold the holy grail in Alzheimer's treatment. But once highflying SAVA stock has plummeted in a firestorm this year. 
Via Investor's Business Daily
Cassava Sciences Has Value and Is Likely To Proceed to Phase 3
SAVA stock still has an implied upside of 67.9% to $78 per share, even if there is a 50% chance that either the shorts or longs are right. 
Via InvestorPlace
46 Biggest Movers From Yesterday
Gainers Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special dividend of $3.50 per share. Onion Global Limited... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Progenity (NASDAQ:PROG) shares increased by 17.0% to $1.1 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 40.5... 
Via Benzinga
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results. BELLUS Health Inc. (NASDAQ: BLU) shares... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
20 21 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.